SCHEMBL536490

SCHEMBL536490

[CH2]O[Si](C)(C)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.39
ESR2 Q92731 1/20 0.39
NR1H2 P55055 2/20 0.32
NR1H3 Q13133 2/20 0.32
TP53 P04637 1/20 0.32
CA4 P22748 1/20 0.32
MAPT P10636 1/20 0.31
BRD4 O60885 1/20 0.31
BRD2 P25440 1/20 0.31
LMNA P02545 1/20 0.30
TSHR P16473 1/20 0.30
ALOX12 P18054 1/20 0.30
ACHE P22303 1/20 0.30
PTGS1 P23219 1/20 0.30
PTGS2 P35354 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL121414 0.78 ESR1 (0.42) ESR1ESR2NR1H2NR1H3CA4
SCHEMBL48955 0.76 ESR1 (0.41) ESR1ESR2NR1H2NR1H3CA4
SCHEMBL13835936 0.75 ESR1 (0.37) ESR1ESR2NR1H2NR1H3MAPT
SCHEMBL18125 0.74 ESR1 (0.39) ESR1ESR2NR1H2NR1H3CA4
SCHEMBL13621387 0.74 ESR1 (0.39) ESR1ESR2NR1H2NR1H3CA4
SCHEMBL13621398 0.74 ESR1 (0.39) ESR1ESR2NR1H2NR1H3CA4
SCHEMBL211428 0.74 ESR1 (0.39) ESR1ESR2NR1H2NR1H3CA4
SCHEMBL11488036 0.74 ESR1 (0.39) ESR1ESR2NR1H2NR1H3CA4
SCHEMBL2248044 0.74 ESR1 (0.39) ESR1ESR2NR1H2NR1H3CA4
SCHEMBL2349819 0.73 ESR1 (0.35) ESR1ESR2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110669058-A Tricyclic quinolone carboxylic acid and preparation method thereof 江西农业大学 2020-01-10 CN claimed
EP-1329160-A2 4-ACYLAMINOPYRAZOLE DERIVATIVES Sankyo Company, Limited (JP) 2003-07-23 EP claimed
EP-3060236-B1 POLYNUCLEOTIDE, POLYPEPTIDE WITH IMMUNOSUPPRESIVE ACTIVITY, EXPRESSION CASSETTE, EXPRESSION VECTOR, HOST CELL, PHARMACEUTICAL COMPOSITION AND METHODS FOR PRODUCING A POLYPETIDE WITH IMMUNOSUPPRESIVE ACTIVITY AND FOR PREVENTING OR TREATING CONDITIONS THAT REQUIRE IMMUNOSUPPRESION FUND BUTANTAN (BR) 2020-12-02 EP disclosed
US-10081660-B2 Polynucleotide, polypeptide with immunosuppressive activity, expression cassette, expression vector, host cell, pharmaceutical composition, methods for producing a polypeptide with immunosuppressive activity and for preventing or treating conditions that require immunosuppression, and use of a polypeptide FUNDAÇÃO BUTANTAN (BR) 2018-09-25 US disclosed
US-20160311869-A1 Polynucleotide, Polypeptide with Immunosuppressive Activity, Expression Cassette, Expression Vector, Host Cell, Pharmaceutical Composition, Methods for Producing a Polypeptide with Immunosuppressive Activity and for Preventing or Treating Conditions That Require Immunosuppression, and Use of a Polypeptide FUNDAÇÃO BUTANTAN (BR) 2016-10-27 US disclosed
EP-3060236-A1 POLYNUCLEOTIDE, POLYPEPTIDE WITH IMMUNOSUPPRESIVE ACTIVITY, EXPRESSION CASSETTE, EXPRESSION VECTOR, HOST CELL, PHARMACEUTICAL COMPOSITION, METHODS FOR PRODUCING A POLYPETIDE WITH IMMUNOSUPPRESIVE ACTIVITY AND FOR PREVENTING OR TREATING CONDITIONS THAT REQUIRE IMMUNOSUPPRESION AND USE OF A POLYPEPTIDE Fundação Butantan (BR) 2016-08-31 EP disclosed
US-9099744-B2 Particulate porous carbon material and use thereof in lithium cells BASF SE (DE) 2015-08-04 US disclosed
WO-2015058275-A1 POLYNUCLEOTIDE, POLYPEPTIDE WITH IMMUNOSUPPRESIVE ACTIVITY, EXPRESSION CASSETTE, EXPRESSION VECTOR, HOST CELL, PHARMACEUTICAL COMPOSITION, METHODS FOR PRODUCING A POLYPETIDE WITH IMMUNOSUPPRESIVE ACTIVITY AND FOR PREVENTING OR TREATING CONDITIONS THAT REQUIRE IMMUNOSUPPRESION AND USE OF A POLYPEPTIDE CRISTÁLIA PRODUTOS QUÍMICOS FARMACÊUTICOS LTDA (BR) 2015-04-30 WO disclosed
US-8992801-B2 Electroactive material, and use thereof in anodes for lithium-ion cells BASF SE (DE) 2015-03-31 US disclosed
EP-2415106-B1 ELECTROACTIVE MATERIAL AND ITS USE IN ANODES FOR LITHIUM-ION CELLS BASF SE (DE) 2014-08-20 EP disclosed
US-8680203-B2 Process for producing a particulate nanocomposite material BASF SE (DE) 2014-03-25 US disclosed
US-5700938-A Intermediates for imidazopyridine derivatives EISAI CO., LTD. (JP) 1997-12-23 US disclosed
US-5618969-A Intermediates for imidazopyridines EISAI CO., LTD. (JP) 1997-04-08 US disclosed
US-5608068-A Process for the preparation of imidazopyridine derivatives and intermediates EISAI CO., LTD. (JP) 1997-03-04 US disclosed
US-5587504-A Sulfonyloxy-biphenylcarboxylic ester derivatives which are intermediates EISAI CO., LTD. (JP) 1996-12-24 US disclosed
US-5583229-A Process for the preparation of imidazopyridine derivatives EISAI CO., LTD. (JP) 1996-12-10 US disclosed
US-5559236-A Intermediates for substituted biphenylmethylmidazopyridine angiotensin II antagonists EISAI CO., LTD. (JP) 1996-09-24 US disclosed
US-5557002-A Process for the preparation of biphenyl containing intermediates useful in making angiotensin II receptor antagonists EISAI CO., LTD. (JP) 1996-09-17 US disclosed
US-5554757-A Process for the preparation of imidazopyridine derivatives, and intermediates therefore EISAI CO., LTD. (JP) 1996-09-10 US disclosed
EP-0627433-A1 PROCESS FOR PRODUCING IMIDAZOPYRIDINE DERIVATIVE AND INTERMEDIATE Eisai Co., Ltd. (JP) 1994-12-07 EP disclosed